MEDP

MEDP

USD

Medpace Holdings Inc. Common Stock

$594.530+8.583 (1.465%)

Цена в режиме реального времени

Healthcare
Diagnostics & Research
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$585.947

Максимум

$599.990

Минимум

$580.451

Объем

0.05M

Фундаментальные показатели компании

Рыночная капитализация

16.7B

Отрасль

Diagnostics & Research

Страна

United States

Статистические данные торговли

Средний объем

0.34M

Биржа

NMS

Валюта

USD

52-недельный диапазон

Минимум $250.05Текущая $594.530Максимум $625

Связанные новости

Reuters

Indian pharmacy retailer MedPlus profit jumps with store opening push

Medplus Health Services , one of India's top retail pharmacy chains, reported a 43.3% rise in second-quarter profit on Friday, driven by higher sales from new store openings and steady demand for its private label products.

Просмотреть больше
Indian pharmacy retailer MedPlus profit jumps with store opening push
Analyst Upgrades

TD Cowen Maintains Sell on Medpace Hldgs, Raises Price Target to $462

TD Cowen analyst Charles Rhyee maintains Medpace Hldgs with a Sell and raises the price target from $356 to $462.

Просмотреть больше
TD Cowen Maintains Sell on Medpace Hldgs, Raises Price Target to $462
Analyst Upgrades

Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $485

Barclays analyst Luke Sergott maintains Medpace Hldgs with a Underweight and raises the price target from $425 to $485.

Просмотреть больше
Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $485
Analyst Upgrades

Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655

Mizuho analyst Ann Hynes maintains Medpace Hldgs with a Outperform and raises the price target from $575 to $655.

Просмотреть больше
Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655
Analyst Upgrades

Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins

Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 guidance.

Просмотреть больше
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins
BusinessWire

Medpace Holdings, Inc. Reports Third Quarter 2025 Results

Revenue of $659.9 million in the third quarter of 2025 increased 23.7% from revenue of $533.3 million for the comparable prior-year period, representing a backlog conversion rate of 23.0%. Net new business awards

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.